Synairgen plc (SYGGF)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
+0.0001 (9,900.00%)
At close: Jan 7, 2026
Synairgen Company Description
Synairgen plc discovers and develops drugs for respiratory diseases.
It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein, which orchestrates the body's antiviral responses.
Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Synairgen plc
| Country | United Kingdom |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Joseph Colliver |
Contact Details
Address: Mailpoint 810 Southampton, SO16 6YD United Kingdom | |
| Phone | 44 23 8051 2800 |
| Website | synairgen.com |
Stock Details
| Ticker Symbol | SYGGF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB00B0381Z20 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Joseph Tregonning Colliver F.C.A. | Chief Executive Officer and Executive Director |
| Prof. Stephen T. Holgate CBE, M.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. Mark Parry-Billings Ph.D. | Executive Chairman |
| Prof. Donna Davies | Co-Founder and Member of Scientific Advisory Board |
| Prof. Ratko Djukanovic | Co-Founder and Member of Scientific Advisory Board |
| Andy Lee | Finance Director |
| Dr. Gareth E. Walters Ph.D. | Chief Regulatory Officer |
| Jody Brookes | Senior Vice President and Head of Clinical Operations |
| Dr. Marcin Mankowski M.D. | CMO and Head of Scientific Affairs |
| Simon William Holden Esq. | Company Secretary |